Navigation Links
Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
Date:7/23/2013

New York, NY (PRWEB) July 23, 2013

Signal Genetics today announced that the results of a retrospective Weill Cornell validation study of BreastPRS, a novel series of prognostic and molecular profiling algorithms for breast cancer, has been published in the medical journal ‘Breast Cancer Research and Treatment’. Signal Genetics, LLC, is a privately held molecular diagnostic company based in New York, NY and Little Rock, AR.

Ryan Van Laar, Ph.D., Head of Bioinformatics & New Product Development at Signal Genetics said “We are excited about the results of this independent study, which determines that our BreastPRS test has the potential to provide physicians improved breast cancer prognostication and more critical personalized information. It is now much more than a viable alternative.”

The publication is titled “BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.”[1]. The study was performed by re-analyzing breast cancer tissue from 246 Weill Cornell patients whose tissue had previously been analyzed with Oncotype DX® by Genomic Health® (CA) . Gene expression analysis and BreastPRS calculations were performed in Signal Genetics’ CLIA-certified laboratory in Little Rock, AR.

The correlation between recurrence score and risk groups generated from the Oncotype DX and BreastPRS methods was highly statistically significant (P < 0.0001). Notably BreastPRS was found to reclassify Oncotype DX intermediate-risk patients into two groups with significant differences in recurrence free survival, potentially offering physicians an alternative method of breast cancer prognostication, which includes molecular grade and molecular subtyping algorithms to provide a comprehensive personalized analysis of each patient’s disease.

BreastPRS has also been used by researchers at the Windber Research Institute (Windber, PA) to examine the impact of recent ASCO/CAP guideline changes for determining ER status. The study was published in the Annals of Surgical Oncology (2013 Jan; 20(1): 87-93)

Signal Genetics is seeking licensing partners to further develop BreastPRS as a stand-alone prognostic test for patients with breast cancer. For more information contact Signal Genetics by emailing info(at)signalgenetics(dot)com.

[1] Timothy M. D’Alfonso, et al. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast Cancer Research and Treatment. June 2013, Volume 139, Issue 3, pp 705-715

Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.

Read the full story at http://www.prweb.com/releases/signalgenetics/breastprs/prweb10947060.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Needle beam could eliminate signal loss in on-chip optics
2. Physicists skirt thermal vibration, transfer optical signal via mechanical oscillator
3. Laser-like photons signal major step towards quantum Internet
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
6. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
10. Cytogenetics - Technologies, Markets and Companies
11. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The Energy and Resources Institute ... producing mycorrhizae. The Centre for Mycorrhizal Research at TERI ... and developed a technology that eventually produces mycorrhizae based ... ... The TERI facility has a production capacity of over ...
(Date:1/12/2017)... 12, 2017 The report "Direct-Fed Microbials Market by Type (Lactic Acid ... Liquid), and Region - Global Forecast to 2022", published by MarketsandMarkets, the global ... projected to reach USD 1,399.6 Million by 2022, at a CAGR of 6.96% ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Ovation Fertility™ Genetics ... reliable preimplantation genetic screening (PGS). , “Our genetics and IVF teams are recognized ... Genetics Scientific Director Amy Jones, M.S., ELD (ABB) , who has worked ...
(Date:1/11/2017)... 11, 2017  Brian Mehling, M.D., world-renowned stem cell ... Horizon International (BHI), will be attending the 47th Annual ... from January 17-20, 2017. This will be Dr. ... The theme of this year,s forum is Responsive and ... will address strategies for fostering greater social inclusion and ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):